CD4 and Huntington disease: As for the ESKD-HD population, there was a significant reduction in naïve (RTE and CD4CD45RA+CCR7+) (Table 3) and early differentiated subtypes (CD4CD45RA+CD28+, CD4CD28+CD57−, CD4CD45RA+CD57−, CD4CD45RA-CD57−), compared to healthy controls; however, no differences were found in the allocation of the different CD4+ subtypes (naïve 35.8 (16)% vs. 33.7 (17)%, CM 59 (18)% vs. 56.3 (20)%, EM 0.7 (1)% vs. 1 (1.8)%, EMRA 2 (2)% vs. 1.9 (4)%, respectively; Figure 3.